Article
Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
Antimicrobial agents and chemotherapy - 10 Jan 2024
Pandey Sushil, Vilchèze Catherine, Werngren Jim, Bainomugisa Arnold, Mansjö Mikael, Groenheit Ramona, Miotto Paolo, Cirillo Daniela M, Coulter Christopher, Baulard Alain R, Schön Thomas, Jacobs William R, Djaout Kamel, Köser Claudio U
Abstract excerpt
Results from clinical strains and knockouts of the H37Rv and CDC1551 laboratory strains demonstrated that ndh (Rv1854c) is not a resistance-conferring gene for isoniazid, ethionamide, delamanid, or pretomanid in Mycobacterium tuberculosis. This difference in the susceptibility to NAD-adduct-forming drugs compared with other mycobacteria may be driven by differences in the absolute intrabacterial NADH concentration.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.